^
Association details:
Biomarker:No biomarker
Cancer:Osteosarcoma
Regimen:MAP (cisplatin + doxorubicin hydrochloride + methotrexate IV)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
11/20/2020
Excerpt:
Osteosarcoma: First-line therapy (primary/neoadjuvant/adjuvant therapy or metastatic disease)…Preferred Regimens…MAP (high-dose methotrexate, cisplatin, and doxorubicin) (Category 1)